The World Health Organization (WHO) says, “around 846 million people aged between 15 and 49 are living with genital herpes infections – more than 1 in 5 of this age-group globally – according to new estimates.
According to a Study of Tecovirimat for Mpox (STOMP) analysis, “tecovirimat did not reduce the time to lesion resolution or have an effect on pain among adults with mild to moderate clade II mpox and a low risk of developing severe disease.”
Have you experienced an unacceptable QC result in your lab? Troubleshooting an out-of-control event in a clinical laboratory requires a systematic approach to recover from the event and prevent its recurrence.
